On The Pen With Dave Knapp

Bleav, Dave Knapp Founder of On The Pen
  • 4.9 (326)
  • MEDICINE
  • UPDATED WEEKLY

Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!

  1. GLP-1 State of the Union

    17H AGO

    GLP-1 State of the Union

    Get Exclusive OTP Savings! Https://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    46 min
  2. Lower Cost Zepbound and Wegovy? TrumpRX Announcement Incoming

    NOV 4

    Lower Cost Zepbound and Wegovy? TrumpRX Announcement Incoming

    Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    46 min
  3. Eli Lilly Earnings Call Recap: NEW GLP-1 GIP Peptide Announced!

    OCT 30

    Eli Lilly Earnings Call Recap: NEW GLP-1 GIP Peptide Announced!

    EXCLUSIVE SAVINGS FOR YOU! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    24 min
  4. Retatrutide + Tirzepatide Grey Market Clampdown + 1 Billion GLP-1 Pills Incoming

    OCT 28

    Retatrutide + Tirzepatide Grey Market Clampdown + 1 Billion GLP-1 Pills Incoming

    GET EXCLUSIVE OTP SAVINGS! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    30 min
  5. HLTH 2025: Obesity Care Superstar Interviews

    OCT 22

    HLTH 2025: Obesity Care Superstar Interviews

    VIEW EXCLUSIVE OTP SAVINGS! http://otplinks.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    50 min
  6. TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!

    OCT 17

    TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!

    GET ACCESS TO OBESITY CARE AND MEDS AND SUPPORT OTP: https://lddy.no/1ndi6 USE CODE: OTP25 VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    30 min

  7. OCT 14

    Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory

    Visit our Sponsors and check out EXCLUSIVE OTP Savings! www.OTPLinks.com www.tryshed.com (use code OTP25 to save 25%) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    28 min
  8. Retatrutide News That Could Change Everything for GLP-1 Compounds

    OCT 7

    Retatrutide News That Could Change Everything for GLP-1 Compounds

    SUPPORT OUR WORK: OTPLinks.com 💉 Story 1 — Fractyl Health’s One-and-Done Gene Therapy for Obesity Fractyl Health just dropped preclinical results showing their GLP-1 + GIP gene therapy candidate RJVA-002 produced almost 30% weight loss in mice after a single dose. I sat down with Dr. Harith Rajagopalan, CEO of Fractyl Health, to talk about how this new Rejuva® platform works, what it means for people living with obesity and type 2 diabetes, and why gene therapy might be the future of metabolic care. 🏛️ Story 2 — Medicare Coverage for GLP-1s? Dr. Oz Drops a Hint At the Aspen Institute, CMS Administrator Dr. Mehmet Oz said even a comment on GLP-1 coverage would be “market moving.” We break down what that means, why the Trump administration shelved a rule that would’ve added obesity meds to Medicare coverage, and how that decision might now be a bargaining chip to lower drug prices in exchange for tougher enforcement on compounding. ⚖️ Story 3 — The Retatrutide Ruling and the Future of Compounded Access A federal judge ruled the FDA acted “arbitrarily and capriciously” when it rejected Lilly’s bid to classify retatrutide as a biologic. That may sound technical, but if the FDA changes its stance, it could have huge implications for tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic)—especially when it comes to compounding and patient access. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    40 min
See All (156)

4.9
out of 5
326 Ratings

About

Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!

Information

  • Creator
    Bleav, Dave Knapp Founder of On The Pen
  • Years Active
    2024 - 2025
  • Episodes
    156
  • Rating
    Explicit
  • Copyright
    © 2025 On The Pen With Dave Knapp
  • Show Website
    On The Pen With Dave Knapp

You Might Also Like